Evidence map›Paper›PMID 34712665›Full record

ArticleFrontiers in cell and developmental biology2021

Regulatory T Cells Improved the Anti-cirrhosis Activity of Human Amniotic Mesenchymal Stem Cell in the Liver by Regulating the TGF-β-Indoleamine 2,3-Dioxygenase Signaling.

Zhenhua Deng, Jinren Zhou, Xiaoxin Mu, Jian Gu, Xiangyu Li, Qing Shao, Jinyang Li, Chao Yang, Guoyong Han, Jie Zhao and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Zhenhua DengHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Liver Cancer Institute, Nanjing Medical University, Nanjing, China.
Jinren ZhouHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Liver Cancer Institute, Nanjing Medical University, Nanjing, China.
Xiaoxin MuHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Liver Cancer Institute, Nanjing Medical University, Nanjing, China.
Jian GuHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Liver Cancer Institute, Nanjing Medical University, Nanjing, China.
Xiangyu LiHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Liver Cancer Institute, Nanjing Medical University, Nanjing, China.
Qing ShaoHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Liver Cancer Institute, Nanjing Medical University, Nanjing, China.
Jinyang LiHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Liver Cancer Institute, Nanjing Medical University, Nanjing, China.
Chao YangHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Liver Cancer Institute, Nanjing Medical University, Nanjing, China.
Guoyong HanHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Liver Cancer Institute, Nanjing Medical University, Nanjing, China.
Jie ZhaoHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Liver Cancer Institute, Nanjing Medical University, Nanjing, China.
Yongxiang XiaHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Liver Cancer Institute, Nanjing Medical University, Nanjing, China.
Nanjing Medical University · CNJiangsu Province Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver fibrosis is a progression stage of chronic liver disease, while current therapies cannot cure or attune cirrhosis effectively. Human amniotic mesenchymal stromal cell (hAMSC) presented immunoregulatory and tissue repairability of multiple illnesses. Regulatory T cells (Treg) had been proved to be functional in reducing immune cell activity. We showed that co-infusion of hAMSC and Treg prevented mild liver fibrosis comparing with hAMSC or Treg alone group.

Indexed as

hAMSCIDOliver cirrhosisTGF-βTreg

Identifiers

PMID34712665
PMCPMC8545991
OpenAlexW3206258458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.